First-line afatinib followed by osimertinib in patients with EGFR mutation-positive NSCLC: Real-world data and clinical experience
21 Jan 2020
byDr. Akito Hata
Since the discovery of epidermal growth factor receptor (EGFR) as a molecular target for non-small–cell lung cancer (NSCLC), first-, second-, and third-generation EGFR tyrosine kinase inhibitors (TKIs) have been developed. However, the optimal sequencing of these agents to maximize the duration of EGFR-TKI treatment has yet to be elucidated. GioTag is a global real-world study investigating sequential treatment with afatinib and osimertinib. Dr Akito Hata, Director of Department of Thoracic Oncology, Kobe Minimally Invasive Cancer Center in Kobe, Japan, discusses the role of afatinib in EGFR mutation-positive NSCLC in light of the GioTag data and shares his clinical experience with the GioTag sequence.
